Companies: 10,795·Total market cap: $144.5T
Immuneering Corporation

Immuneering Corporation

IMRXNASDAQHealthcare● Active
$4.04
$-0.23(-5.39%)
Market Cap$146661444
P/E Ratio—
52W High$10.08
52W Low$1.66
SEC Filings

Immuneering Corporation (IMRX) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001790340 · IMRX · NASDAQ · as of Jun 8, 2026

Filing snapshot

306
Total Filings
8-K
Latest Form
2026-06-01
Most Recent
2021
Filing Since
FinancialsEarningsView All on EDGAR

Source: SEC EDGAR (data.sec.gov) · CIK 0001790340 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2026-03-06
Fiscal Year End
Mar 6, 2026
Accession No.
0001790340-26-000042
Primary Document
imrx-20251231.htm
View on SEC EDGARDownload PDFFiling Index
Source: data.sec.gov · CIK 0001790340 · Accession 0001790340-26-000042

Latest Key Filings

10-QQuarterly Report
10-Q
2026-05-15
View 10-Q on SEC
8-KCurrent Report
8-K
2026-06-01Material Event
View 8-K on SEC
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

View Insider Trades Tab

SEC Filing History

Hide Form 4 / 144
8-KCurrent Report
8-K
2026-06-01
View
10-QQuarterly Report
10-Q
2026-05-15
View
8-KCurrent Report
8-K
2026-05-15
View
DEFA14AProxy Statement (Additional)
DEFA14A
2026-04-20
View
DEF 14AProxy Statement
DEF 14A
2026-04-20
View
10-KAnnual Report
10-K
2026-03-06
View
8-KCurrent Report
8-K
2026-03-06
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-01-22
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-01-15
View
8-KCurrent Report
8-K
2026-01-07
View
10-QQuarterly Report
10-Q
2025-11-12
View
8-KCurrent Report
8-K
2025-11-12
View
SCHEDULE 13GSCHEDULE 13G
SCHEDULE 13G
2025-10-21
View
SCHEDULE 13GSCHEDULE 13G
SCHEDULE 13G
2025-10-07
View
SCHEDULE 13GSCHEDULE 13G
SCHEDULE 13G
2025-10-03
View
Showing 1–15 of 170 filingsForm 4 / 144 hidden· 306 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001790340  |  Exchange: NASDAQ · Healthcare

Immuneering Corporation (NASDAQ: IMRX) has submitted 306 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2021. As a Healthcare sector company with CIK 0001790340, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Immuneering Corporation's most comprehensive regulatory disclosure. The most recent Immuneering Corporation 10-K was filed on 2026-03-06 for fiscal year ending 2026. Historical IMRX 10-K annual reports are available from 2019 through 2026.

Investors researching Immuneering Corporation SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-08
Related Companies SEC Filings — Healthcare
ASMB SEC Filings →NAUT SEC Filings →ENTA SEC Filings →TRDA SEC Filings →HUMA SEC Filings →ZURA SEC Filings →FHTX SEC Filings →ARCT SEC Filings →
→ IMRX Financials→ IMRX Earnings→ IMRX Insider Trades

Frequently Asked Questions

IMRX SEC Filings · 8 questions

Immuneering Corporation (IMRX) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 306 filings and access original documents at no cost. Immuneering Corporation's CIK is 0001790340.

IMRX SEC filingsImmuneering Corporation SEC documentsfind IMRX 10-K